Fulltext available Open Access
DC FieldValueLanguage
dc.contributor.advisorReintjes, Ralf-
dc.contributor.authorAhmad, Amena
dc.date.accessioned2020-09-29T12:04:26Z-
dc.date.available2020-09-29T12:04:26Z-
dc.date.created2007
dc.date.issued2007-05-10
dc.identifier.urihttp://hdl.handle.net/20.500.12738/6218-
dc.description.abstractBackground: Cervical cancer constitutes a major burden of disease with nearly 500,000 new cases each year, 83% of which are seen in the developing world. More than 6500 cases of invasive cervical cancer are diagnosed in Germany annually with the mean age at diagnosis being 52 years. It constitutes 3.4% of all cancers in women, yet it accounts for 25% of cancers in the 25 –35 year age group. Human Papillomavirus (HPV) infection which is the most common sexually transmitted infection has been proposed as the first ever necessary cause of a human cancer associated with more than 99.7% of cervical cancers. Of the more than 130 genotypes identified 15 types have been labelled as high risk types. In view of the promising research results of prophylactic HPV VLP vaccines, this review aims to explore the public health potential which the introduction of such a prophylactic vaccine could have in the German context and to identify the influencing factors. Discussion: Impact of HPV vaccination on cervical cancer incidence at population level will depend on the length of induced immunity, number and interval of booster doses required, vaccine coverage of population at risk, societal acceptance and costs involved. If results from the large scale trials are similar to the phase II trials and model calculations hold true, given a high vaccine coverage a HPV vaccination would have a profound effect in reducing the burden of cervical disease in Germany.en
dc.language.isoenen
dc.rights.urihttp://rightsstatements.org/vocab/InC/1.0/-
dc.subjectHuman Papillomavirus vaccinationen
dc.subjectPublic Healthen
dc.subjectGermanyen
dc.subjectCervical cancer preventionen
dc.subject.ddc610 Medizin, Gesundheit
dc.titlePublic Health Implications of Human Papilloma Virus Vaccination: With Reference to the German Situationen
dc.typeThesis
openaire.rightsinfo:eu-repo/semantics/openAccess
thesis.grantor.departmentDepartment Gesundheitswissenschaften
thesis.grantor.placeHamburg
thesis.grantor.universityOrInstitutionHochschule für angewandte Wissenschaften Hamburg
tuhh.contributor.refereePebody, Richard-
tuhh.gvk.ppn528714481
tuhh.identifier.urnurn:nbn:de:gbv:18302-reposit-62207-
tuhh.note.externpubl-mit-pod
tuhh.note.intern1
tuhh.oai.showtrueen_US
tuhh.opus.id217
tuhh.publication.instituteDepartment Gesundheitswissenschaften
tuhh.type.opusMasterarbeit-
dc.subject.gndImpfung
dc.subject.gndPapillomaviren
dc.subject.gndDeutschland
dc.subject.gndÖffentliches Gesundheitswesen
dc.subject.gndGebärmutterhalskrebs
dc.type.casraiSupervised Student Publication-
dc.type.dinimasterThesis-
dc.type.drivermasterThesis-
dc.type.statusinfo:eu-repo/semantics/publishedVersion
dc.type.thesismasterThesis
dcterms.DCMITypeText-
tuhh.dnb.statusdomain-
item.languageiso639-1en-
item.fulltextWith Fulltext-
item.creatorGNDAhmad, Amena-
item.creatorOrcidAhmad, Amena-
item.grantfulltextopen-
item.cerifentitytypePublications-
item.openairetypeThesis-
item.advisorGNDReintjes, Ralf-
item.openairecristypehttp://purl.org/coar/resource_type/c_46ec-
Appears in Collections:Theses
Files in This Item:
File Description SizeFormat
med_y_202.pdf661.23 kBAdobe PDFView/Open
Show simple item record

Page view(s)

88
checked on Jun 16, 2024

Download(s)

56
checked on Jun 16, 2024

Google ScholarTM

Check

HAW Katalog

Check

Note about this record


Items in REPOSIT are protected by copyright, with all rights reserved, unless otherwise indicated.